Bangladesh vs Pakistan: Average cost of multi drug-resistant tuberculosis treatment
Bangladesh
466 constant 2022 US$
in 2024
Pakistan
460 constant 2022 US$
in 2024
Bangladesh rank
81st
Pakistan rank
82nd
Average cost of multi drug-resistant tuberculosis treatment over time
- Bangladesh
- Pakistan
How they compare
Bangladesh currently reports 466 constant 2022 US$ against 460 constant 2022 US$ in Pakistan, a difference of 6 constant 2022 US$.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Pakistan ahead.
Bangladesh ranks 81st and Pakistan ranks 82nd of 92 countries.
Pakistan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bangladesh | Pakistan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,374 constant 2022 US$ | 3,783 constant 2022 US$ | 2,409 constant 2022 US$ | Pakistan |
| 2020s | 769 constant 2022 US$ | 1,406 constant 2022 US$ | 637.4 constant 2022 US$ | Pakistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Bangladesh or Pakistan?
- Bangladesh, at 466 constant 2022 US$ against 460 constant 2022 US$ in Pakistan as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Bangladesh and Pakistan?
- 6 constant 2022 US$, with Bangladesh ahead.
- How many years of comparable data are there for Bangladesh and Pakistan?
- 8 years are reported by both, from 2017 to 2024.
- How do Bangladesh and Pakistan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Bangladesh ranks 81st and Pakistan ranks 82nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.